非HLA单核苷酸多态性能否帮助对TrialNet中有1型糖尿病风险的亲属进行风险分层?
本研究利用免疫芯片分析1016例抗体阳性非西班牙裔白人1型糖尿病高危亲属的53个非HLA糖尿病相关SNP,采用Cox比例风险模型评估其对多抗体及糖尿病进展的影响,发现5个非HLA SNP与进展风险增加相关,可能改善预防试验的风险分层。
要点
- 在抗体阳性非西班牙裔白人亲属中,rs3087243(细胞毒性T淋巴细胞相关蛋白4)与从单抗体进展为多抗体相关。
- rs6476839(GLIS3)和rs3184504(SH2B3)与糖尿病进展显著相关。
- 年龄分层后,<12岁者中rs4900384(C14orf64)与进展显著相关,≥12岁者中rs3184504(SH2B3)和rs4900384(C14orf64)显著。
核心结论
- 研究识别出5个非HLA SNP与从抗体阳性进展至1型糖尿病的风险增加相关,可能改善预防试验的风险分层。
研究设计与样本
- TrialNet Pathway to Prevention研究随访1型糖尿病患者亲属,使用免疫芯片分析1016例抗体阳性、有风险的非西班牙裔白人亲属的53个糖尿病相关非HLA SNP。
主要发现
- 从单抗体进展为多抗体的因素包括筛查时年龄、与先证者的关系、HLA基因型和rs3087243(细胞毒性T淋巴细胞相关蛋白4)。
- 糖尿病进展的显著因素包括筛查时年龄、抗体数量、HLA基因型、rs6476839(GLIS3)和rs3184504(SH2B3)。
- 纳入葡萄糖曲线下面积(AUC)后,疾病进展因素包括葡萄糖AUC、筛查时年龄、抗体数量、与先证者的关系、HLA基因型、rs6476839(GLIS3)和rs7221109(CCR7)。
- 在<12岁参与者中,葡萄糖AUC、筛查时年龄、同胞、HLA基因型、rs6476839(GLIS3)和rs4900384(C14orf64)与糖尿病进展显著相关;在≥12岁者中,葡萄糖AUC、同胞、rs3184504(SH2B3)和rs4900384(C14orf64)显著。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Genome-wide association studies identified >50 type 1 diabetes (T1D) associated non-human leukocyte antigens (non-HLA) loci. OBJECTIVE: The purpose of this study was to assess the contribution of non-HLA single nucleotide polymorphisms (SNPs) to risk of disease progression. DESIGN AND SETTING: The TrialNet Pathway to Prevention Study follows relatives of T1D patients for development of autoantibodies (Abs) and T1D. PARTICIPANTS: Using the Immunochip, we analyzed 53 diabetes-associated, non-HLA SNPs in 1016 Ab-positive, at-risk non-Hispanic white relatives. MAIN OUTCOME MEASURE: Effect of SNPs on the development of multiple Abs and T1D. RESULTS: Cox proportional analyses included all substantial non-HLA SNPs, HLA genotypes, relationship to proband, sex, age at initial screening, initial Ab type, and number. Factors involved in progression from single to multiple Abs included age at screening, relationship to proband, HLA genotypes, and rs3087243 (cytotoxic T lymphocyte antigen-4). Significant factors for diabetes progression included age at screening, Ab number, HLA genotypes, rs6476839 [GLIS family zinc finger 3 (GLIS3)], and rs3184504 [SH2B adaptor protein 3 (SH2B3)]. When glucose area under the curve (AUC) was included, factors involved in disease progression included glucose AUC, age at screening, Ab number, relationship to proband, HLA genotypes, rs6476839 (GLIS3), and rs7221109 (CCR7). In stratified analyses by age, glucose AUC, age at screening, sibling, HLA genotypes, rs6476839 (GLIS3), and rs4900384 (C14orf64) were significantly associated with progression to diabetes in participants <12 years old, whereas glucose AUC, sibling, rs3184504 (SH2B3), and rs4900384 (C14orf64) were significant in those ≥12. CONCLUSIONS: In conclusion, we identified five non-HLA SNPs associated with increased risk of progression from Ab positivity to disease that may improve risk stratification for prevention trials.
引用
- Steck AK, Xu P, Geyer S, et al. Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes? J Clin Endocrinol Metab. 2017. PMID: 28520980. doi:10.1210/jc.2016-4003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。